Published in

BioMed Central, Journal of Translational Medicine, 1(10), 2012

DOI: 10.1186/1479-5876-10-218

Links

Tools

Export citation

Search in Google Scholar

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

Journal article published in 2012 by Adrian Bot, Mark Ahn, Marnix Bosch, Dirk Brockstedt, Lisa H. Butterfield, W. Martin Kast, Andrew Cornforth, Richard Harrop, W. Martin Kast, Richard Koya, Francesco M. Marincola, Kim Margolin, Candice McCoy, Graham Pawelec ORCID, John Rothman and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.